Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $60K for lobbying in Q2 2023 · Health Issues

Trade details

Type
Lobbying report
Amount
$60,000
Quarter
Q2 2023
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
23/07/16

Up 20.0% from last quarter

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 23/05/31~23/07/30

Ultragenyx Pharmaceutical's other lobbying reports

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $60K for lobbying in Q2 2023 · Health Issues | Whalegun